WithdrawnNot Applicable

Hybrid Closed-Loop Insulin Delivery System in Type 1 Diabetes Candidates for a Living Donor Kidney Transplant

Stopped: PI was unable to enroll anyone.

United States0Started 2018-08-31

Plain-language summary

The investigators' primary aim is to determine the impact of using hybrid closed-loop (HCL) system in patients with type 1 diabetes (T1D) and end stage renal disease (ESRD) prior to kidney transplantation. The investigators will also determine whether HCL, by improving glucose control, will affect short-term (1 month) and long-term (12 months) complications after kidney transplantation in patients with T1D.

Who can participate

Age range18 Years – 65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Type 1 diabetes * Recipient of (historical controls) or on waiting list for (cohort) a living donor kidney transplant. Exclusion Criteria: * Cohort and Historical Controls: * Vision, hearing impairment (patients cannot recognize the pump and sensor signals and alarms) * Cognitive impairment (unless 24-hour caregiver is available) * Total daily insulin dose requirements less than 8 units per day * Patients who are not willing to check their blood glucose test at least twice a day * Not followed/do not plan be followed at Yale New Haven Hospital * Cohort: * No living donor candidate

What they're measuring

Duration of use of hybrid closed-loop (HCL) system

Timeframe: up to 1 year post-surgery

Trial details

NCT IDNCT03494010

SponsorYale University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2020-04-30

View on ClinicalTrials.gov More Diabetes, Type 1 trials